Match!
Celina Ang
Memorial Sloan Kettering Cancer Center
35Publications
3H-index
58Citations
Publications 35
Newest
Last.Celina AngH-Index: 3
view all 3 authors...
Source
#1Celina AngH-Index: 3
#2Samuel J. KlempnerH-Index: 19
Last.Sherri Z. MillisH-Index: 11
view all 11 authors...
// Celina Ang 1 , Samuel J. Klempner 2 , Siraj M. Ali 3 , Russell Madison 3 , Jeffrey S. Ross 3 , Eric A. Severson 3 , David Fabrizio 3 , Aaron Goodman 4 , Razelle Kurzrock 4 , James Suh 3 and Sherri Z. Millis 3 1 Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Mount Sinai Hospital, New York, NY, USA 2 Department of Medicine, Division of Hematology/Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA 3 Foundation Medicine, Cambridge, MA, USA 4 Department o...
Source
OBJECTIVE:In the United States, hepatocellular carcinoma (HCC) is more common among communities with low socioeconomic status (SES), and these groups tend to be diagnosed with later-stage cancers. Sorafenib is the primary treatment for advanced HCC, however its substantial cost raises concern for access to treatment. METHODS:The newly developed Case-Background method was used to estimate odds ratios for the impacts of various sociodemographic factors on sorafenib access in clinically eligible pa...
Source
#1Celina AngH-Index: 3
#2Anthony F. ShieldsH-Index: 45
Last.John L. MarshallH-Index: 44
view all 10 authors...
// Celina Ang 1 , Anthony Shields 2 , Joanne Xiu 3 , Zoran Gatalica 4 , Sandeep Reddy 3 , Mohamed E. Salem 5 , Carol Farhangfar 6 , Jimmy Hwang 7 , Igor Astsaturov 3, 7 and John L. Marshall 5 1 Department of Medicine, Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA 2 Department of Oncology, Molecular Imaging & Diagnostics Program, Karmanos Cancer Center, Wayne State University, Detroit, MI, USA 3 Department of Medical Affairs, Caris Life Sciences, Phoenix, AZ, USA...
Source
#1Celina AngH-Index: 3
#2Aryeh StollmanH-Index: 1
Last.Sherri Z. MillisH-Index: 1
view all 7 authors...
We report the case of a patient with appendiceal adenocarcinoma with mucinous peritoneal carcinomatosis who was treated with trametinib upon identification of a GNAS R201H mutation
2 CitationsSource
#1Jennifer M. KolbH-Index: 1
#2Umut OzbekH-Index: 7
Last.Celina AngH-Index: 3
view all 5 authors...
Background: Helicobacter pylori (H pylori) infection is a known risk factor for gastric cancer (GC) and has been linked with gastroesophageal junction (GEJ) cancer. Studies examining the relationship between H. pylori infection, GC characteristics and prognosis are limited and have yielded conflicting results. We report on the clinicopathologic characteristics and oncologic outcomes of gastric and GEJ cancer patients with and without a history of H. pylori treated at our institution. Methods: We...
2 CitationsSource
#1Celina AngH-Index: 3
#2Aatur D. SinghiH-Index: 20
Last.Sherri Z. MillisH-Index: 11
view all 8 authors...
599Background: Appendiceal cancers are rare and consist of mucinous (M), adenocarcinoma (A), goblet cell carcinoma (GCC), pseudomyxoma peritonei (PMP), and several even rarer histologies. Current treatment involves surgical resection or debulking; no standard exists for adjuvant chemotherapy or metastatic disease treatment. Systemic treatment is often based on chemotherapy regimens used in colorectal cancer. Methods: Tissue from 518 appendiceal cancer patients was assayed by hybrid-capture based...
Source
#1Nancy E. KemenyH-Index: 78
#2Yuman FongH-Index: 109
Last.Michael I. D’AngelicaH-Index: 70
view all 13 authors...
3577 Background: Previously, we showed thatHAI with FUDR + dexamethasone (Dex) plus SYS produced a 47 % resectability rate in a retrospective study of 49 pts with UnCLM. Methods: Prospectively evaluated UnCLM pts in a new protocol were combined with the above protocol (n=105 pts) and all were treated with HAI FUDR/Dex + Sys. Unresectability was defined as diffuse bilateral metastases, involvement of all hepatic/portal veins, and/or inability to preserve remaining liver with adequate perfusion. F...
3609 Background: There are conflicting results regarding the influence of KRAS mutation status and outcome in patients (pts) with colorectal cancer. A recent report suggested worse outcome in KRAS mutated (MUT) pts who underwent resection of hepatic metastases (Karagkounis et al, ASCO 2012). Methods: Recurrence patterns and survival were evaluated in 169 patients who had undergone resection of liver metastases, then received adjuvant hepatic arterial infusion and systemic chemotherapy, and for w...
#1Celina AngH-Index: 3
#2Anthony F. ShieldsH-Index: 45
Last.John MarshallH-Index: 52
view all 10 authors...
Source
1234